Ana Ruiz-Garcı́a
Gilead Sciences (United States)(US)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Colorectal Cancer Treatments and Studies, Drug Transport and Resistance Mechanisms, Pancreatic and Hepatic Oncology Research, HER2/EGFR in Cancer Research
Most-Cited Works
- → Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study(2009)288 cited
- → Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan–Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer(2012)266 cited
- → PAMPA—a drug absorption in vitro model(2004)204 cited
- → Pharmacokinetics in Drug Discovery(2007)199 cited
- → Phase II study of sunitinib as second-line treatment for advanced gastric cancer(2010)194 cited
- → Establishing Best Practices and Guidance in Population Modeling: An Experience With an Internal Population Pharmacokinetic Analysis Guidance(2013)183 cited
- → A phase 2 trial of dacomitinib (PF‐00299804), an oral, irreversible pan‐HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non–small cell lung cancer after failure of prior chemotherapy and erlotinib(2014)142 cited
- → N-Succinyl-chitosan systems for 5-aminosalicylic acid colon delivery: In vivo study with TNBS-induced colitis model in rats(2011)69 cited
- → Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors(2012)63 cited
- → Characterization of Neutropenia in Advanced Cancer Patients Following Palbociclib Treatment Using a Population Pharmacokinetic-Pharmacodynamic Modeling and Simulation Approach(2017)49 cited